Osteoprotegerin ameliorates sciatic nerve crush induced bone loss.

Bateman, Ted A.; Dunstan, Colin R.; Lacey, David L.; Ferguson, Virginia L.; Ayers, Reed A.; Simske, Steven J.

doi:10.1016/s0736-0266(00)00057-7

Cited by 22Bone Metabolism and DiseasesBone health and osteoporosis researchBone and Joint Diseases

Osteoprotegerin ameliorates sciatic nerve crush induced bone loss.

Open access

Bateman, Ted A., Dunstan, Colin R., Lacey, David L., Ferguson, Virginia L., Ayers, Reed A., Simske, Steven J.·2001·Journal of Orthopaedic Research

DOI 10.1016/s0736-0266(00)00057-7

Open this paper in CoChat — free account Open PDF

Abstract

This study examines the ability of osteoprotegerin (OPG) to prevent the local bone resorption caused by sciatic nerve damage. Sixty‐five 18‐week‐old male mice were assigned to one of six groups (n = 10–11/group). A baseline control group was sacrificed on day zero of the 10‐day study. The remaining groups were placebo sham operated, placebo nerve crush (Plac NC) operated, 0.1 mg/kg/day OPG + nerve crush (LOW), 0.3 mg/kg/day OPG + nerve crush (MED), and 1.0 mg/kg/day OPG + nerve crush (HI). Nerve crush or sham operations were performed on the right leg. The left leg served as a contralateral control to the nerve crushed (ipsilateral) leg. The difference in mass between the right and left femur and tibia was examined. Additionally, quantitative histomorphometry was performed on the right and left femur and tibia diaphyses. Nerve crush resulted in a significant loss of bone mass in the ipsilateral side compared to the contralateral side. Bone mass for the ipsilateral bones of the Plac NC group were significantly reduced by 3.8% in the femur and 3.5% in the tibia compared to the contralateral limb. The percent diminution was reduced for OPG treated mice compared to the Plac NC group for both the femur and tibia. In the femur, the percent reduction of ipsilateral bone mass was reduced to 1.0% (LOW), 1.3% (MED) and 1.6% (HI) compared to the contralateral limb. In the tibia, loss of bone mass in the ipsilateral limb was reduced to 1.4% (LOW), 1.4% (MED), and 2.4% (HI) compared to the contralateral. OPG also decreased the amount of tibial endocortical resorption compared to the Plac NC group. In summary, OPG mitigated bone loss caused by damage to the sciatic nerve. © 2001 Orthopaedic Research Society. Published by Elsevier Science Ltd. All rights reserved.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/s0736-0266(00)00057-7

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

OPG reduced cortical bone resorption and increased bone density in mouse nerve crush models.
“OPG reduced cortical bone resorption and increased bone density in mouse nerve crush models (290,291).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [290]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.
Lacey, D. L., Timms, E., Tan, H.-L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81569-x · Cited by 5,439 · see citing works
Self-citation
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130 · see citing works
Self-citation
Bone histomorphometry: Standardization of nomenclature, symbols, and units: Report of the asbmr histomorphometry nomenclature committee
PARFITT, A. M., Drezner, M. K., Glorieux, F. H., Kanis, J. А., Malluche, H. H., Meunier, P. J., Ott, S. M., & Recker, R. R. (1987) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650020617 · Cited by 5,015 · see citing works
Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL
Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S.-I., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.7.3597 · Cited by 4,224 · see citing works
Bone Histomorphometry : Standardization of Nomenclature, Symbols, and Units
PARFITT, A. M., Drezner, M. K., Glorieux, F. H., Kanis, J. А., Malluche, H. H., Meunier, P. J., Ott, S. M., & Recker, R. R. (1987) · Journal of Bone and Mineral Research · Cited by 3,258 · see citing works
Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification.
Bucay, N., Sarosi, I., Dunstan, C. R., Morony, S., Tarpley, J., Capparelli, C., Scully, S., Tan, H. L., Xu, W., Lacey, D. L., et al. (1998) · Genes & Development · doi:10.1101/gad.12.9.1260 · Cited by 2,483 · see citing works
Self-citation
Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand.
Hsu, H., Lacey, D. L., Dunstan, C. R., Solovyev, I., Colombero, A., Timms, E., Tan, H.-L., Elliott, G., Kelley, M. J., Sarosi, I., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.7.3540 · Cited by 1,636 · see citing works
Self-citation
Identity of Osteoclastogenesis Inhibitory Factor (OCIF) and Osteoprotegerin (OPG): A Mechanism by which OPG/OCIF Inhibits Osteoclastogenesis<i>in Vitro</i><sup>1</sup>
Yasuda, H., Shima, N., Nakagawa, N., Mochizuki, S.-I., Yano, K., Fujise, N., Sato, Y., Goto, M., Yamaguchi, K., Kuriyama, M., et al. (1998) · Endocrinology · doi:10.1210/endo.139.3.5837 · Cited by 1,201 · see citing works
Tetracycline-based histological analysis of bone remodeling
Frost, H. M. (1969) · Calcified Tissue Research · doi:10.1007/bf02058664 · Cited by 1,111 · see citing works
Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin.
Mizuno, A., Amizuka, N., Irie, K., Murakami, A., Fujise, N., Kanno, T., Sato, Y., Nakagawa, N., Yasuda, H., Mochizuki, S.-I., et al. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.8697 · Cited by 775 · see citing works
The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts.
Burgess, T. L., Qian, Y.-X., Kaufman, S., Ring, B. D., Van, G., Capparelli, C., Kelley, M., Hsu, H., Boyle, W. J., Dunstan, C. R., et al. (1999) · The Journal of Cell Biology · doi:10.1083/jcb.145.3.527 · Cited by 689 · see citing works
Self-citation
Osteoclast differentiation factor is a ligand for osteoprotegerin/ osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95: 3597-602
Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S.-I., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., et al. (1998) · Cited by 650 · see citing works
A New Member of Tumor Necrosis Factor Ligand Family, ODF/OPGL/TRANCE/RANKL, Regulates Osteoclast Differentiation and Function
Takahashi, N., Udagawa, N., & Suda, T. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.0252 · Cited by 461 · see citing works
A novel molecular mechanism modulating osteoclast differentiation and function
Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Goto, M., Mochizuki, S.-I., Tsuda, E., Morinaga, T., Udagawa, N., et al. (1999) · Bone · doi:10.1016/s8756-3282(99)00121-0 · Cited by 262 · see citing works
A chimeric form of osteoprotegerin inhibits hypercalcemia and bone resorption induced by IL-1β, TNF-α, PTH, PTHrP, and 1,25(OH)2D3.
Morony, S., Capparelli, C., Lee, R., Shimamoto, G., Boone, T., Lacey, D. L., & Dunstan, C. R. (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.9.1478 · Cited by 187 · see citing works
Self-citation
Osteoclastogenesis inhibitory factor suppresses osteoclast survival by interfering in the interaction of stromal cells with osteoclast.
Akatsu, T., Murakami, T., Nishikawa, M., Ono, K., Shinomiya, N., Tsuda, E., Mochizuki, S.-I., Yamaguchi, K., Kinosaki, M., Higashio, K., et al. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.9294 · Cited by 123 · see citing works
Osteoprotegerin and osteoprotegerin ligand effects on osteoclast formation from human peripheral blood mononuclear cell precursors
Shalhoub, V., Faust, J., Boyle, W. J., Dunstan, C. R., Kelley, M., Kaufman, S., Scully, S. A., Van, G. Y., & Lacey, D. L. (1999) · Journal of Cellular Biochemistry · doi:10.1002/(sici)1097-4644(19990201)72:2 · Cited by 123 · see citing works
Self-citation
Cortical tibial bone volume in two strains of mice: effects of sciatic neurectomy and genetic regulation of bone response to mechanical loading
Kodama, Y., Dimai, H.-P., Wergedal, J. R., Sheng, M. H. ‐., Malpe, R., Kutílek, Š., Beamer, W. G., Donahue, L. R., Rosen, C. J., Baylink, D. J., et al. (1999) · Bone · doi:10.1016/s8756-3282(99)00155-6 · Cited by 92 · see citing works
Fractures After Myelopathy: The Risk Quantified
Frisbie, J. H. (1997) · Journal of Spinal Cord Medicine · doi:10.1080/10790268.1997.11719458 · Cited by 81 · see citing works
Osteoprotegerin mitigates tail suspension-induced osteopenia.
Bateman, T. A., Dunstan, C. R., Ferguson, V. L., Lacey, D. L., Ayers, R. A., & Simske, S. J. (2000) · Bone · doi:10.1016/s8756-3282(00)00256-8 · Cited by 66 · see citing works
Self-citation
Bone marrow capacity for bone cells and trabecular bone turnover in immobilized tibia after sciatic neurectomy in mice
Sakai, A., Nakamura, T., Tsurukami, H., et al. (1996) · Bone · doi:10.1016/8756-3282(96)00042-7 · Cited by 63 · see citing works
ERK Pathway Mediates the Activation of Cdk2 in IGF-1–Induced Proliferation of Human Osteosarcoma MG-63 Cells
Zhang, W., Lee, J. C., Kumar, S., & Gowen, M. (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.4.528 · Cited by 61 · see citing works
Early modifications of biochemical markers of bone metabolism in spinal cord injury patients. A preliminary study
Uebelhart, D., Hartmann, D. J., Vuagnat, H., Castanier, M., Hachen, H. J., & Chantraine, A. (1994) · Journal of Rehabilitation Medicine · doi:10.2340/165019771994264197202 · Cited by 61 · see citing works
The Effect of Pulsing Electromagnetic Fields on Bone Metabolism in Experimental Disuse Osteoporosis
Cruess, R. L., Kan, K. W., & Bassett, C. A. L. (1983) · Clinical Orthopaedics and Related Research · doi:10.1097/00003086-198303000-00034 · Cited by 58 · see citing works
A distinct difference between slow and fast muscle in acetylcholinesterase recovery after reinnervation in the rat
Dettbarn, W. (1981) · Experimental Neurology · doi:10.1016/0014-4886(81)90147-3 · Cited by 38 · see citing works
Treatment of sciatic denervation disuse osteoporosis in the rat tibia with capacitively coupled electrical stimulation. Dose response and duty cycle.
Brighton, C. T., Tadduni, G. T., & Pollack, S. R. (1985) · Journal of Bone and Joint Surgery · doi:10.2106/00004623-198567070-00005 · Cited by 37 · see citing works
Nerve crush induced changes in molecular forms of acetylcholinesterase in soleus and extensor digitorum muscles
Groswald, D. E., & Dettbarn, W. (1983) · Experimental Neurology · doi:10.1016/0014-4886(83)90230-3 · Cited by 36 · see citing works
Postinjury changes in the biomechanics of nerves and roots in mice
Luttges, M. W., Stodieck, L., & Beel, J. A. (1986) · Clinical Biomechanics · doi:10.1016/0268-0033(86)90155-5 · Cited by 9 · see citing works

Flagged first, then by citations

Research works printed but not linked: 7

1554527x, 2001, 4, Downloaded from https://onlinelibrary.wiley.com/doi/10.1016/S0736-0266(00)00057-7, Wiley Online Library on [05/06/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License
De Bastinani G, Nogarin L, Perusi M. Pig calcitonin in the treatment of localized osteoporosis. Ital J Orthop Traumatol 1976;2: 181-90.
Fleet ML. The effect of developmental stage on the mouse response to induced osteopenia. Ph.D. dissertation, University of Colorado, Boulder, CO, 1996.
Mizuno A, Amizuka N, Irie K, Murakami A, Fujise N, Kanno T, et al. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factodosteoprotegerin. Biochem Biophys Res Commun 1998;247:610-5.
Shalhoub V, Faust J, Boyle WJ, Dunstan CR. Kelley M, Kaufman S, et a]. Charicterizaion of OPGL-induced osteoclast formation from peripheral bood mononuclear cell precursors. Bone 1998;23:S217.
Simske SJ, Schmeister TA, Fleet ML, Broz JJ, Gayles EC, Luttges MW. An experimental model for combined neural, muscular, and skeletal degeneration. JNMS 1994;2:116-23.
Takahashi N, Udagawa N, Suda T. A new member of tumor necrosis factor ligand family, ODFIOPGLITRANCEIRANKL, regulates osteoclast differentiation and function. Biochem Biophys Res Commun 1999;256:449-55.

Sorted by citations

Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease
Kearns, A. E., Khosla, S., & Kostenuik, P. J. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0014 · Cited by 824 · see citing works
Osteoprotegerin Reduces Osteoclast Numbers and Prevents Bone Erosion in Collagen-Induced Arthritis
Romas, E., Sims, N. A., Hards, D. K., Lindsay, M., Quinn, J. W. M., Ryan, P. F. J., Dunstan, C. R., Martin, T. J., & Gillespie, M. T. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64417-3 · Cited by 368 · see citing works
Self-citation

The functional recovery of peripheral nerves following defined acute crush injuries
Chen, L., Seaber, A. V., Glisson, R. R., et al. (1992) · Journal of Orthopaedic Research® · doi:10.1002/jor.1100100508 · Cited by 86 · see citing works
High-freqency ultrasonographic observation on the acute crush injury of sciatic nerve in rabbits
He, J. (2007) · Shengwu yixue gongcheng yu linchuang
Low-Level Laser Irradiation Improves Functional Recovery and Nerve Regeneration in Sciatic Nerve Crush Rat Injury Model
Wang, C., Chen, Y., Wang, Y., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103348 · Cited by 98 · see citing works
Enhancement of regeneration by Org 2766 after nerve crush depends on the type of neural injury
Tonnaer, J. A. D. M., Schuijers, G. J. P. T., Diepen, H. A. V., et al. (1992) · European Journal of Pharmacology · doi:10.1016/0014-2999(92)90092-i · Cited by 11 · see citing works
Observation on the acute crush injury of sciatic nerve in rabbits by high-frequency ultrasonography
Xiao-dong, Z. (2006) · Medical Journal of National Defending Forces in Northwest China

Authors: Bateman, T. A., Dunstan, C. R., Lacey, D. L., Ferguson, V. L., Ayers, R. A., & Simske, S. J.
Affiliations: University of Colorado Boulder (US)
Amgen (United States) (US)
Corresponding author: Bateman, Ted A.
ORCID: Dunstan, Colin R.
Ferguson, Virginia L.
Ayers, Reed A.
Venue: Journal of Orthopaedic Research
Publisher: Wiley
Published: 2001-07
Volume: 19
Issue: 4
Pages: 518-523
ISSN: 0736-0266 (ISSN-L)
1554-527X
DOI: 10.1016/s0736-0266(00)00057-7
OpenAlex: W1981825950
Cited by: 22
References: 28
Citations by year: 2025: 1 · 2024: 1 · 2023: 1 · 2022: 2 · 2021: 1 · 2019: 2 · 2016: 1
FWCI: 0.58
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor, 1645 d)
Locations: Journal of Orthopaedic Research® (publishedVersion)
PubMed (publishedVersion)
Funders: National Aeronautics and Space Administration
Amgen
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone and Joint Diseases
Keywords: osteoprotegerin, sciatic nerve crush injury, bone loss, bone resorption, peripheral nerve injury, bone mass, femur, tibia, bone histomorphometry
MeSH terms: Animals, Bone Resorption, Disease Models, Animal, Femur, Glycoproteins, Humerus, Male, Mice, Inbred C57BL, Nerve Crush, Organ Size, Sciatic Nerve, Tibia, Receptors, Tumor Necrosis Factor, Receptors, Cytoplasmic and Nuclear, Diaphyses, Mice, Osteoprotegerin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Osteoprotegerin ameliorates sciatic nerve crush induced bone loss.

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Related

Record

About these checks